GlassScriptPhysician profile
Rebecca Shaffer
NPI 1104932805
$6,488.37
in general payments reported to CMS, 2019-2025
18 companies · $97.78 in 2025
The $97.78 reported for 2025 was less than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,380 · 2020: $777 · 2021: $1,373 · 2022: $1,155 · 2023: $940 · 2024: $765 · 2025: $97.78.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,803.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,803.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $2,534.97 | 2019-2025 | |
| Viiv Healthcare Company | $1,552.42 | 2019-2025 | Cabenuva, Dovato, Rukobia |
| Merck Sharp & Dohme LLC | $535.90 | 2019-2025 | Dificid, Zerbaxa, Recarbrio |
| Abbvie INC. | $511.26 | 2019-2024 | Avycaz |
| Janssen Biotech, INC. | $401.46 | 2019-2023 | Symtuza |
| Insmed, INC. | $186.03 | 2019-2021 | |
| Theratechnologies INC. | $148.94 | 2019-2022 | |
| La Jolla Pharmaceutical Company | $146.68 | 2022-2024 | Xerava, Xacduro |
| Paratek Pharmaceuticals, INC. | $140.26 | 2019-2022 | |
| Napo Pharmaceuticals INC | $98.32 | 2019-2022 | |
| Shionogi INC | $51.70 | 2022-2023 | Fetroja |
| Allergan, INC. | $49.51 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $28.48 | 2021 | |
| Janssen Scientific Affairs, LLC | $25.20 | 2019 | |
| Pfizer INC. | $23.88 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Institutional INC. | $20.59 | 2019 | |
| Fortovia Therapeutics, INC. | $16.94 | 2019 | |
| Glaxosmithkline, LLC. | $15.83 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rebecca Shaffer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.